CytoDyn (STU:296) Cyclically Adjusted Book per Share: €-0.05 (As of Feb. 2026)


STU:296 CytoDyn Inc STU:296
28 GF Score
Price €0.20
! 1 Warning Sign
View Full Analysis

What is CytoDyn Cyclically Adjusted Book per Share?

CytoDyn STU:296 +3.13% 28 Cyclically Adjusted Book per Share is €-0.05 as of Feb. 2026. GuruFocus rates STU:296 with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

CytoDyn's adjusted book value per share for the three months ended in Feb. 2026 was €-0.065. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-0.05 for the trailing ten years ended in Feb. 2026.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -35.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -0.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of CytoDyn was 34.10% per year. The lowest was -35.70% per year. And the median was 9.20% per year.

As of today (2026-07-04), CytoDyn's current stock price is €0.198. CytoDyn's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2026 was €-0.05. CytoDyn's Cyclically Adjusted PB Ratio of today is .


CytoDyn  (STU:296) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


CytoDyn Cyclically Adjusted Book per Share Related Terms


CytoDyn Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for CytoDyn's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Cyclically Adjusted Book per Share Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.02 -0.03 -0.06 -0.04

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.04 -0.05 -0.04 -0.05

STU:296 vs VSTM, IRD, PALI: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, CytoDyn's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CytoDyn's Cyclically Adjusted PB Ratio falls into.


STU:296
28GF Score
CytoDyn Inc STU:296
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytoDyn's adjusted Book Value per Share data for the three months ended in Feb. 2026 was:

Adj_Book= Book Value per Share /CPI of Feb. 2026 (Change)*Current CPI (Feb. 2026)
=-0.065/326.7850*326.7850
=-0.065

Current CPI (Feb. 2026) = 326.7850.

CytoDyn Quarterly Data

Book Value per Share CPI Adj_Book
201605 0.073 240.229 0.099
201608 0.045 240.849 0.061
201611 0.036 241.353 0.049
201702 0.034 243.603 0.046
201705 -0.007 244.733 -0.009
201708 -0.046 245.519 -0.061
201711 -0.066 246.669 -0.087
201802 -0.029 248.991 -0.038
201805 -0.051 251.588 -0.066
201808 -0.073 252.146 -0.095
201811 -0.024 252.038 -0.031
201902 -0.018 252.776 -0.023
201905 -0.024 256.092 -0.031
201908 -0.016 256.558 -0.020
201911 -0.031 257.208 -0.039
202002 -0.009 258.678 -0.011
202005 -0.004 256.394 -0.005
202008 0.004 259.918 0.005
202011 -0.009 260.229 -0.011
202102 -0.021 263.014 -0.026
202105 -0.028 269.195 -0.034
202108 -0.033 273.567 -0.039
202111 -0.016 277.948 -0.019
202202 -0.028 283.716 -0.032
202205 -0.124 292.296 -0.139
202208 -0.115 296.171 -0.127
202211 -0.138 297.711 -0.151
202302 -0.119 300.840 -0.129
202305 -0.110 304.127 -0.118
202308 -0.115 307.026 -0.122
202311 -0.109 307.051 -0.116
202402 -0.112 310.326 -0.118
202405 -0.102 314.069 -0.106
202408 -0.063 314.796 -0.065
202411 -0.069 315.493 -0.071
202502 -0.072 319.082 -0.074
202505 -0.068 321.465 -0.069
202508 -0.068 323.976 -0.069
202511 -0.082 324.122 -0.083
202602 -0.065 326.785 -0.065

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-0.05 mean?
CytoDyn (STU:296) has a Cyclically Adjusted Book per Share of €-0.05 as of Feb. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CytoDyn and its competitors.
Is CytoDyn's Cyclically Adjusted Book per Share too high?
CytoDyn's current Cyclically Adjusted Book per Share is €-0.05. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Cyclically Adjusted Book per Share compare to VSTM and IRD?
CytoDyn's Cyclically Adjusted Book per Share of €-0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CytoDyn and its competitors. CytoDyn's current Cyclically Adjusted Book per Share is €-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Cyclically Adjusted Book per Share of €-0.05. The current Cyclically Adjusted Book per Share is €-0.05. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For CytoDyn (STU:296), the current Cyclically Adjusted Book per Share is €-0.05 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score

Get the complete analysis for STU:296

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price